In Part II of this blog series we look at recent transactions in the arena of contract research organization, with a particular focus on private equity investing in CROs.
Contract research organizations (CRO) provide research services support for the biotechnology, medical device and pharmaceutical industries on a contractual basis. They offer such services as preclinical and clinical research, clinical trials management, biopharmaceutical development and pharmacovigilance. CROs run the gamut … Continue Reading
During recent months, private equity firms have been actively selling and buying dental practices, which some investors believe is a relatively stable and recession-proof health-care arena. With an aging population requiring more dental work, minimal government intervention and mostly private-pay, … Continue Reading
Dental practice management companies have been an increasing focus of private equity firms throughout the United States and Canada. As the cost of healthcare increases, small dental practices, like private medical practices, will soon be an anomaly. Thus, it is … Continue Reading
As we round out our series on private equity investing in dialysis, we note an emergence in overseas dialysis investing by U.S. investors. Our blog typically focuses on U.S. investing but can’t help but note the interest in overseas … Continue Reading
A few weeks ago, McGuireWoods hosted our 8th Annual Healthcare & Life Sciences Private Equity & Finance Conference along with co-sponsor McGladrey. The Hon. Bill Frist gave the keynote address. It was a real treat to … Continue Reading